Literature DB >> 33660425

Targetable pathogenic mechanisms in nasal polyposis.

Alexander L Schneider1, Robert P Schleimer1,2, Bruce K Tan1,2.   

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.
© 2021 ARS-AAOA, LLC.

Entities:  

Keywords:  biologic therapies; chronic rhinosinusitis with nasal polyps; type 2 inflammation

Mesh:

Substances:

Year:  2021        PMID: 33660425      PMCID: PMC8316260          DOI: 10.1002/alr.22787

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   5.426


  158 in total

1.  Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D2 and cysteinyl leukotrienes in allergic rhinitis.

Authors:  Ichiro Tojima; Koji Matsumoto; Hirotaka Kikuoka; Shiori Hara; Sayuri Yamamoto; Shino Shimizu; Hideaki Kouzaki; Takeshi Shimizu
Journal:  Allergy       Date:  2019-08-12       Impact factor: 13.146

2.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

Authors:  D W MacGlashan; B S Bochner; D C Adelman; P M Jardieu; A Togias; J McKenzie-White; S A Sterbinsky; R G Hamilton; L M Lichtenstein
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

3.  Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus.

Authors:  Tetsuji Takabayashi; Yoshimasa Imoto; Masafumi Sakashita; Yukinori Kato; Takahiro Tokunaga; Kanako Yoshida; Norihiko Narita; Tamotsu Ishizuka; Shigeharu Fujieda
Journal:  Allergol Int       Date:  2017-04-04       Impact factor: 5.836

4.  Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity.

Authors:  Mahboobeh Mahdavinia; Roderick G Carter; Christopher J Ocampo; Whitney Stevens; Atsushi Kato; Bruce K Tan; Robert C Kern; David B Conley; Rakesh Chandra; Kathryn E Hulse; Lydia A Suh; James E Norton; Anju T Peters; Leslie C Grammer; Lawrence B Schwartz; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2014-03-15       Impact factor: 10.793

Review 5.  Immunopathology alters Th17 cell glucocorticoid sensitivity.

Authors:  J Banuelos; Y Cao; S C Shin; N Z Lu
Journal:  Allergy       Date:  2016-10-13       Impact factor: 13.146

Review 6.  Mechanisms of airway hyperresponsiveness.

Authors:  Donald W Cockcroft; Beth E Davis
Journal:  J Allergy Clin Immunol       Date:  2006-09       Impact factor: 10.793

Review 7.  Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.

Authors:  Robert P Schleimer
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

8.  Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

Authors:  Marcia A Chan; Nicole M Gigliotti; Abby L Dotson; Lanny J Rosenwasser
Journal:  Clin Transl Allergy       Date:  2013-09-02       Impact factor: 5.871

9.  Allergic inflammatory memory in human respiratory epithelial progenitor cells.

Authors:  Jose Ordovas-Montanes; Daniel F Dwyer; Sarah K Nyquist; Kathleen M Buchheit; Marko Vukovic; Chaarushena Deb; Marc H Wadsworth; Travis K Hughes; Samuel W Kazer; Eri Yoshimoto; Katherine N Cahill; Neil Bhattacharyya; Howard R Katz; Bonnie Berger; Tanya M Laidlaw; Joshua A Boyce; Nora A Barrett; Alex K Shalek
Journal:  Nature       Date:  2018-08-22       Impact factor: 49.962

Review 10.  Potential new targets for drug development in severe asthma.

Authors:  Linda Zhu; Christina E Ciaccio; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2018-10-25       Impact factor: 4.084

View more
  2 in total

1.  Chronic rhinosinusitis: Future treatments and unmet needs.

Authors:  Sneha Giri; Alexander L Schneider; Bruce K Tan
Journal:  J Allergy Clin Immunol       Date:  2022-06-03       Impact factor: 14.290

2.  Use of intraoperative frontal sinus mometasone-eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Alexander L Schneider; Samuel D Racette; Anthony K Kang; Abhita T Reddy; Julia H Huang; David S Lehmann; Caroline P E Price; Jacob G Eide; Samuel R Rodeghiero; David B Conley; Kevin C Welch; Robert C Kern; Stephanie Shintani-Smith; Anju T Peters; Atsushi Kato; Whitney S Stevens; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2022-04-01       Impact factor: 5.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.